All Posts Tagged With: "drug patent"
Diamonds Are Forever. Why Not a Drug Patent?
Carl Weissman 5/29/09
Tell me if this makes sense to you:
—If I buy a diamond, I can own it for as long as I like;
—If I produce a brand name for a product, provided that I trademark it, I can own it for as long as I would like, until and unless it becomes “generic” (like the term “escalator”, which actually started as a brand name);
—If I write a novel, provided that I copyright protect it, I can own it until I die, and my heirs can maintain those rights for 70 years longer; but,
—If I invent a drug, even if I protect that intellectual property to the full extent of U.S. patent law, I can only own it for 20 years from the date I file for a patent on it.
I can own a tangible good forever, I can own a trademark virtually forever, I can own a copyright for my entire life plus 70 years. But property which is more intrinsically a part of me – my idea, my invention, the product of my intellect – I am only allowed to own that for 20 years after I reveal it to the patent office.
Rationally, it seems obvious that all property – whether tangible or intellectual – should be subject to the same rules and laws of ownership. If you can own a gemstone forever, you should be able to own an invention forever. In fact, if a society wishes to impose differential standards for ownership rights to different types of property, wouldn’t it make more sense that preferential treatment be given to those items which are the product of your talent, your creativity, your self, over those things which you earn or purchase based upon that product of your efforts? The logical extension of this argument, in any free society, is that you should be able to own all property, whether purchased or invented, physical or ethereal, for as long as you wish. Patents, trademarks, copyrights, title – all should be perpetual.
Read the rest of this article on drug patent laws here.
Appeals court upholds Lilly drug patent
Reuters
Tuesday, December 26, 2006; 2:36 PM
WASHINGTON (Reuters) - A U.S. appeals court on Tuesday affirmed the validity of a patent on Eli Lilly and Co.’s (LLY.N) top-selling schizophrenia drug Zyprexa, upholding a 2005 ruling by a federal judge.
The U.S. Court of Appeals for the Federal Circuit said it had found no reversible error in the April 2005 ruling by U.S. District Court Judge Richard Young, which handed Eli Lilly a major victory in its efforts to fend off generic competition.
The patent at issue in the case runs through April of 2011 and had been contested by Israel’s Teva Pharmaceuticals (TEVA.TA)(TEVA.O) and Indian drugmaker Dr. Reddy’s Laboratories (REDY.BO)(RDY.N).
Representatives for Teva and Dr. Reddy’s could not immediately reached for comment.
In 2005, Zyprexa made up 29 percent of Eli Lilly’s $2.6 billion sales. Shares of the drugmaker were up 1.2 percent to $51.96 in afternoon trading on the New York Stock Exchange.
Eli Lilly said the appeals court ruling was a victory for all brand name drug makers.
Read more about Eli Lilly’s drug patent.